Search
Searching Goglides
Loading matching companies, research, topics, and discussions.
Searching Goglides
Loading matching companies, research, topics, and discussions.
Search uses Goglides API results from the projection-backed discovery index. Private, draft, hidden, unpublished, and admin-only content stays out of public results.
Showing public results only.
Firefly Neuroscience pairs an FDA-cleared Evoke EEG/ERP workflow, more than 85 active U.S. clinical sites and a 191,000-record brain-data set with a harder financial reality: Q1 2026 revenue was only $485,000, cash was $3.1 million before subsequent financings
Signed-in searches appear here after you use search.
Tag facets appear after tag usage counts are rebuilt.
AEMD is not a revenue story yet. It is a clinical-stage Hemopurifier bet with FDA Breakthrough Device designations, an Australian oncology trial, a going-concern warning, reverse splits, warrant mechanics and a cash balance that makes every new data point matt
OpenAkso Health Group is pitching an internet-healthcare pivot, but the latest filings show low-margin marketing-promotion revenue, nil interim medical-device revenue, a major impairment and a sharp cash shift into internet-hospital advances.
OpenAlamos Gold is generating record cash flow in a high gold-price environment, but AGI is also asking investors to underwrite a capital-heavy Island Gold District expansion, a 2026 cost decline, hedge cleanup and a path toward materially higher Canadian producti
OpenAduro has a real cash runway after two U.S. offerings, but the decision point is whether Hydrochemolytic Technology can move from customer trials and pilot work into demonstration-scale economics before burn and dilution absorb the runway.
OpenAdagio has pivotal VT data, FDA Breakthrough Device status, and a CE-Marked system, but no current revenue, a going-concern warning, and a cash runway that makes every regulatory milestone matter.
OpenAbbott's Medical Devices engine, led by diabetes care, is doing the heavy lifting while Nutrition weakens and the Exact Sciences acquisition adds cancer-diagnostics upside, debt, and integration risk.
OpenTag facets appear after tag usage counts are rebuilt.